Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

No Abstract Available

Saved in:

Bibliographic Details
Main Authors:	Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain
Format:	Article
Language:	English
Published:	PAGEPress Publications 2010-05-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	Intermediate, high-risk MDS IPSS lenalidomide hematological response dose-modified.
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/183
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Validation and comparison of the molecular international prognostic scoring system (IPSS-M) and the revised international prognostic scoring system (IPSS-R) in myelodysplastic neoplasms (MDS): a retrospective study
by: Mengmeng Hu, et al.
Published: (2025-12-01)

Therapeutic Benefits of Lenalidomide in Hematological Malignancies
by: Mohammed Shafi Abdulsalam, et al.
Published: (2019-04-01)

Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom
by: Drummond M, et al.
Published: (2025-06-01)

Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model‐Informed Precision Dosing for Chinese Population With Renal Insufficiency
by: Yi Ma, et al.
Published: (2025-07-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review
by: Louis Wolff, et al.
Published: (2024-11-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Bioequivalence study between two formulations of 10mg lenalidomide capsules in healthy male subjects under fasting conditions
by: Carlos Sverdloff, et al.
Published: (2023-12-01)

IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation
by: Huixian Wu, et al.
Published: (2025-07-01)

Lenalidomide and its impact on exanthematous reactions: a case report
by: Cristiana Vieira-Maia, et al.
Published: (2025-04-01)

An improved procedure for synthesis of lenalidomide as an active pharmaceutical ingredient
by: Elaheh Ataollahi, et al.
Published: (2025-09-01)

Lenalidomide-induced type II Kounis syndrome: a case report
by: Ruihan Hu, et al.
Published: (2025-06-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome
by: Ying Chen, et al.
Published: (2024-12-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation
by: Qi Huang, et al.
Published: (2025-04-01)

Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone
by: Takuto Tachita, et al.
Published: (2024-07-01)

Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.
by: Jacopo Monticelli, et al.
Published: (2014-12-01)

Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies
by: Mengdi Zhang, et al.
Published: (2025-06-01)

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial
by: Zhengping Li, et al.
Published: (2025-01-01)

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
by: Koki Tamai, et al.
Published: (2024-02-01)

SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy
by: Ioana Martac, et al.
Published: (2024-12-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Hematopoietic Stem Cell Collection in Multiple Myeloma Patients: Influence of the Lenalidomide-Based Therapy and Mobilization Regimen Prior to Auto-HSCT
by: II Kostroma, et al.
Published: (2018-04-01)

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents
by: Alhossain A. Khalafallah, et al.
Published: (2010-04-01)

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents
by: Gerald Bates, et al.
Published: (2010-02-01)

Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
by: Rongqi Li, et al.
Published: (2024-12-01)

Intermediate-dose cytarabine alone versus combination in consolidation therapy for non-transplant acute myeloid leukemia: a retrospective study
by: Yu Liu, et al.
Published: (2025-12-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

Radiation hematologic toxicity prediction in rectal cancer: a comparative radiomics-based study on CT image and dose map
by: Yingpeng Liu, et al.
Published: (2025-03-01)

Dose formation and hematologic effects with prolonged internal exposure of rats by isotope 131I
by: E. A. Sova, et al.
Published: (2014-12-01)

Association between lymphocyte-associated ratios, C-reactive protein and prognostic value in myelodysplastic syndromes
by: Hong-kai Cai, et al.
Published: (2025-12-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)